Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CBLB | Q13191 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596284 | 0.88 | — | — | |
| SCHEMBL32686596 | 0.84 | MAP4K4 (0.42) | QPCTQPCTLEPHX2MAP4K4CBLB | |
| SCHEMBL12050015 | 0.81 | EPHX2 (0.46) | QPCTQPCTLEPHX2MAP4K4KMT2A | |
| SCHEMBL239491 | 0.79 | MEN1 (0.46) | QPCTQPCTLEPHX2MAP4K4KMT2A | |
| SCHEMBL1991333 | 0.79 | MAP4K4 (0.38) | QPCTQPCTLEPHX2MAP4K4POLB | |
| SCHEMBL10205188 | 0.75 | EPHX2 (0.43) | QPCTQPCTLEPHX2MAP4K4KMT2A | |
| SCHEMBL17896807 | 0.74 | MAP4K4 (0.42) | QPCTQPCTLEPHX2MAP4K4 | |
| SCHEMBL20691034 | 0.73 | MEN1 (0.37) | QPCTQPCTLEPHX2MAP4K4KMT2A | |
| SCHEMBL20691035 | 0.72 | MAP4K4 (0.40) | QPCTQPCTLEPHX2MAP4K4KMT2A | |
| SCHEMBL17896787 | 0.72 | MAP4K4 (0.48) | QPCTQPCTLEPHX2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | claimed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7144887-B2 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2003-07-03 | — | — | US | disclosed |
| EP-1242423-A1 | SUBSTITUTED 1,2,3-TRIAZOLO 1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044250-A1 | SUBSTITUTED 1,2,3-TRIAZOLO[1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | QPCT 2447/4885QPCTL 2557/4885EPHX2 3249/4885 |
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | HAX1, HTR1D, CHRM1 | QPCT 373/4885QPCTL 805/4885EPHX2 1434/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | QPCT 3444/4885QPCTL 3854/4885EPHX2 1872/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | QPCT 4235/4885QPCTL 4220/4885EPHX2 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.